Displaying drugs 2201 - 2225 of 14998 in total
Lenvatinib
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular...
Approved
Investigational
Matched Description: … differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression ... 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. ... kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Pitavastatin
Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively...
Approved
Matched Iupac: … (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid …
Matched Description: … hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid ... lipid levels and ultimately reduce the risk of cardiovascular disease. ... studies to significantly reduce the risk of development of CVD and all-cause mortality. …
Matched Description: … hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid ... lipid levels and ultimately reduce the risk of cardiovascular disease. ... studies to significantly reduce the risk of development of CVD and all-cause mortality. …
Piflufolastat F 18
Prostate cancer is the most common non-cutaneous malignancy affecting men in North America - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and location of tumor metastases and recurrences. The images generated by positron emission tomography (PET) are less detailed than those...
Approved
Investigational
Matched Iupac: … 2S)-2-({[(1S)-1-carboxy-5-{[6-(¹⁸F)fluoropyridin-3-yl]formamido}pentyl]carbamoyl}amino)pentanedioic acid …
Matched Description: … location of tumor metastases and recurrences. ... and more accurate detection of suspected prostate cancer metastases or recurrences. ... despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Description: … location of tumor metastases and recurrences. ... and more accurate detection of suspected prostate cancer metastases or recurrences. ... despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Aminophenazone
Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function tests. The FDA suspended the use of aminophenazone due to its association...
Approved
Withdrawn
Matched Description: … Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries …
Edoxudine
Edoxudine is a deoxythymidine analog with activity against herpes simplex virus. It is a potent and selective inhibitor of herpes simplex virus type 1 and 2. The obtained product is an antiviral ointment. The activity of edoxudine against herpes simplex virus was first recognized in 1967. It was later recognized...
Approved
Investigational
Withdrawn
Matched Description: … It is a potent and selective inhibitor of herpes simplex virus type 1 and 2. ... [A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992 …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Lymecycline
Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections.[L13880,L13883] It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK...
Approved
Investigational
Matched Iupac: … methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-yl]formamido}methyl)amino]-2-aminohexanoic acid …
Matched Description: … Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and ... has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and ... It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. …
Matched Description: … Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and ... has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and ... It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. …
Levallorphan
An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties. It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants. (From Martindale, The Extra Pharmacopoeia,...
Approved
Tamoxifen
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers...
Approved
Matched Description: … treatment for these types of cancers as patients generally have better survival, side effect profiles, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Phenprocoumon
Coumarin derivative that acts as a long-acting oral anticoagulant.
Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs …
Idarubicin
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Approved
Matched Description: … The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Propafenone
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Approved
Lurbinectedin
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin (trabectedin), an anticancer agent found in extracts of the tunicate...
Approved
Investigational
Matched Description: … including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,[A214322] and ... [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed ... in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Glofitamab
Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.[L45698,A258488]
Glofitamab was approved...
Approved
Investigational
Matched Description: … It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting ... antigens found on B- and T-cells, respectively. ... Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Cisapride
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Approved
Investigational
Withdrawn
Matched Description: … The FDA issued a warning letter regarding this risk to health care professionals and patients. …
Matched Categories: … Alimentary Tract and Metabolism ... Benzamides and benzamide derivatives …
Matched Categories: … Alimentary Tract and Metabolism ... Benzamides and benzamide derivatives …
Dexamethasone acetate
Commonly known as decadron, dexamethasone acetate is a glucocorticosteroid previously marketed in the USA for the treatment of inflammatory respiratory, allergic, autoimmune, and other conditions.[T797,L10695,L14348] Developed in 1957, dexamethasone is structurally similar to other corticosteroids such as hydrocortisone and prednisolone. Dexamethasone acetate has largely been replaced by dexamethasone phosphate and...
Approved
Investigational
Vet approved
Matched Description: … one-third in patients on oxygen therapy and mechanical ventilation, respectively. ... previously marketed in the USA for the treatment of inflammatory respiratory, allergic, autoimmune, and ... [A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues …
Lifileucel
Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.
Approved
Investigational
Matched Description: … suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …
Glymidine
Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta...
Approved
Investigational
Matched Description: … Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and ... appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and ... ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Hexamidine
Approved
Experimental
Matched Categories: … Biguanides and Amidines ... Antiseptics and Disinfectants ... Ophthalmological and Otological Preparations …
Amisulpride
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in...
Approved
Investigational
Matched Description: … D2 and D3 receptors. ... , and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major ... Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine …
Matched Categories: … Benzamides and benzamide derivatives …
Matched Categories: … Benzamides and benzamide derivatives …
Cyclopenthiazide
Cyclopenthiazide is a thiazide diuretic with antihypertensive properties. In a double blind, randomized crossover study, cyclopenthiazide was effective in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients . It is a positive allosteric modulator at AMPA-A receptors .
Approved
Matched Categories: … cyclopenthiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... cyclopenthiazide and potassium-sparing agents ... Low-Ceiling Diuretics and Potassium-Sparing Agents …
Medrogestone
Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. It was never approved by the FDA.
Approved
Withdrawn
Matched Description: … [A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing …
Matched Categories: … medrogestone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Progestogens and Estrogens, Sequential Preparations …
Matched Categories: … medrogestone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Progestogens and Estrogens, Sequential Preparations …
Polistes annularis venom protein
Polistes annularis venom protein is an extract of Polistes annularis venom. Polistes annularis venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Besifloxacin
Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
Approved
Matched Iupac: … 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …
Siponimod
Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphingosine-1-phosphate (S1P) receptor modulator and is thought to...
Approved
Investigational
Matched Iupac: … cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid …
Matched Description: … , disrupting communication between the brain and other parts of the body. ... It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. ... [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Description: … , disrupting communication between the brain and other parts of the body. ... It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. ... [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Ozenoxacin
To date, ozenoxacin has been used in trials studying the treatment of impetigo.
As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by Staphylococccus aureus or Streptococcus pyogenes in adult and pediatric patients...
Approved
Investigational
Matched Iupac: … cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …
Matched Description: … has demonstrated safe and effective therapy in both the adult and pediatric population. ... pediatric patients 2 months of age and older. ... Despite being a common and highly contagious bacerial skin infection that affects millions of children …
Matched Description: … has demonstrated safe and effective therapy in both the adult and pediatric population. ... pediatric patients 2 months of age and older. ... Despite being a common and highly contagious bacerial skin infection that affects millions of children …
Displaying drugs 2201 - 2225 of 14998 in total